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Over the past decade, alternative splicing has been progressively recognized as a major mechanism regulating gene expression
patterns in different tissues and disease states through the generation of multiple mRNAs from the same gene transcript. This
process requires the joining of selected exons or usage of different pairs of splice sites and is regulated by gene-specific combinations
of RNA-binding proteins. One archetypical splicing regulator is SRSF1, for which we review the molecular mechanisms and
posttranscriptional modifications involved in its life cycle. These include alternative splicing of SRSF1 itself, regulatory protein
phosphorylation events, and the role of nuclear versus cytoplasmic SRSF1 localization. In addition, we resume current knowledge
on deregulated SRSF1 expression in tumors and describe SRSF1-regulated alternative transcripts with functional consequences for
cancer cell biology at different stages of tumor development.
1. Introduction
The expression of a gene is initiated by its transcription
into a precursor messenger RNA (mRNA), which is then
further processed and spliced into a mature mRNA. Splic-
ing is regulated through the interaction between RNA-
binding proteins (RBPs) and their cognate splicing regulatory
sequence elements (SREs) in the mRNA. This is especially
important for alternative splicing wheremultiplemRNAs can
be generated from the same pre-mRNA through the joining
of selected exons or usage of different pairs of splice sites [1].
The number of genes encoding RBPs in the human
genome is currently estimated to be around 860 [2, 3], far
below the number of around 200 000 transcripts that can
be produced from the roughly 21 000 human protein-coding
genes. Therefore, a key principle in splicing regulation is that
the interaction of RNA-binding proteins with SREs is not a
one-to-one relationship: each SREmotif can be recognized by
multiple alternativeRBPs andmost splicing factors can recog-
nize two or more SRE motifs. This is particularly relevant for
alternative splicing events, the regulation of which involves
a complex network of competing protein-RNA interactions
so that individual exons can be controlled by multiple factors
[4, 5]. For example, multiple RNA-binding proteins with
similar splicing regulatory activities might bind the same
motif and this functional redundancy creates robustness in a
splicing decision. Also, some factors compete with or displace
another factor with opposite activity and confer functional
antagonism. These overlapping binding specificities allow
regulatory plasticity, which underlies tissue-specific splicing
patterns, subtle fine-tuning of splice variant levels, and regu-
latory relationships between splicing regulators and upstream
signaling pathways.
Among the RBPs, the major classes of splicing fac-
tors that control splice site recognition are the families
of Serine/Arginine-rich (SR) proteins and heterogeneous
nuclear ribonucleoproteins (hnRNPs). These proteins act
by selecting splice sites for recognition by the spliceosome
through binding to intronic or exonic splice enhancer and
silencer elements and promoting or destabilizing protein
interactions with spliceosome components. One of the best
studied factors is SRSF1, formerly known as ASF or SF2 [6].
SRSF1 is a prototypical splicing factor mostly recruited to
SREs classified as exonic splicing enhancers (ESEs). SRSF1
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recognizes degenerate purine-rich sequence motifs [7, 8] and
its binding promotes recognition of both constitutive and
alternative exons during spliceosomal assembly. The current
knowledge about its regulationwill be the focus of this review.
The described principles of regulation also apply to many
other SR proteins and RBPs.
2. Posttranscriptional Regulation of
SRSF1 mRNA
The SRSF1 gene is essential for normal embryonic develop-
ment that is constitutively expressed and tightly regulated at
the posttranscriptional level. In particular, SRSF1 recognizes
SREs in its own transcripts, leading to alternative splicing,
with some transcript forms being degraded by nonsense-
mediated mRNA decay (NMD). In case of SRSF1, alternative
splicing occurs in the 3󸀠 untranslated region following exci-
sion of an additional intron and thus introduction of a new
exon-exon junction. In consequence, the original stop codon
is recognized as premature and the transcript targeted for
NMD [9].Thismechanism is highly conserved and shared by
other SR proteins. It serves both as a negative feedback loop,
in which increased SR protein levels promote an increase in
unproductive splice variants of their own transcripts, and as a
target for regulation, for example, depending on the ERK1/2-
mediated phosphorylation status of the splicing regulator
Sam68 [10].
In addition, other posttranscriptional mechanisms of
SRSF1 autoregulation were described such as nuclear reten-
tion of alternative SRSF1 transcript variants or regulation of
the translational efficiency of its transcripts [11, 12]. Further-
more, miRNAs targeting SRSF1 translation have begun to be
identified, including miR-28, miR-505, miR-10a, and miR-
10b [13, 14]. Thus, SRSF1 transcript levels are fine-tuned by
various posttranscriptional mechanisms but the quantitative
contribution of each step and their orchestration in response
to different cellular stimuli remains undetermined.
3. SRSF1 Regulation by Protein
Phosphorylation
Following translation of SRSF1 transcripts into protein, con-
stitutive phosphorylation steps occur. First, the predomi-
nantly cytoplasmic SR-specific protein kinases (SRPKs) phos-
phorylate part of the C-terminal Arg-Ser-rich (RS) domain,
which contains 20 serine residues. SRPK1 was shown to
phosphorylate the proximal first 12 residues [15] and this pro-
motes nuclear import through interaction of phospho-SRSF1
with the import factor transportin-SR2 [16] and subsequent
localization into nuclear speckles [17, 18].
Once in the nucleus the Cdc2-like kinases (CLKs) phos-
phorylate the remaining serine residues in the distal RS
domain which leads to dispersed nuclear localization of
SRSF1 and is required for its function in splicing [19–21]
through cotranscriptional association with RNA polymerase
II (pol2). Upon transcription inhibition SRSF1 is translocated
from the nucleoplasm back to nuclear speckles [22] (see
Figure 1 for a graphic summary).
Recently, it was found that SRPK1 can also shuttle into the
nucleus [23–26] where then SRPK1 and CLK1 display similar
activities toward Arg-Ser repeats in the distal RS domain,
suggesting that these kinases no longer operate in a strict
linear manner along the RS domain. Instead, CLKs appear
to recognize preferentially the three Ser-Pro dipeptides in the
RS domain, the phosphorylation of which has been proposed
to change the conformation of the RS domain and regulate
SRSF1 contact sites required in the spliceosome [27]. Nuclear
translocation of SRPK1 can be induced, for example, by
stress conditions, and involves disruption of its binding to a
cytoplasmic Hsp70/Hsp90 complex [28].
Besides these phosphorylation events considered to be
constitutive, other protein kinases have been reported to
regulate SRSF1 through phosphorylation.
Protein kinase A (PKA) can phosphorylate SRSF1 on
serine 119 in vitro and modulate its activity as a splicing
factor [29, 30]. This phosphorylation occurs in the so-called
pseudo-RNA recognition motif (RRM) and was described to
change the RNA-binding properties of SRSF1 and reduce its
capacity to activate splicing.
Human DNA topoisomerase I (topo I) has also been
described to phosphorylate SRSF1 [31, 32], most likely in
the RS domain. This phosphorylation promotes the binding
of SRSF1 to cognate ESEs during alternative splicing events
[33]. The DNA damage signal poly-ADP ribose forms a
complex with SRSF1, and this promotes Topo I to switch
from its protein kinase to DNA relaxation activity [34]. A
further connection between SRSF1 and Topo I is their role
in preventing R-loop formation, stable mRNA:DNA hybrids
that can form following transcription [35, 36].
Another kinase reported to phosphorylate SRSF1 in vitro
is AKT [37, 38], which also targets serine residues in the
RS domain, leading to altered splicing decisions. A subse-
quent study reported that AKT1 interacts with and promotes
SRPK1 and SRPK2 autophosphorylation and their subse-
quent translocation into the nucleus [26] with simultaneous
formation of a phosphatase containing complex to downreg-
ulate AKT activity [39]. It remains to be established whether
AKT phosphorylates SRSF1 directly or whether the described
activity of immunoprecipitated AKT to phosphorylate SRSF1
originates from associated SRPKs.
The serine/threonine kinase NEK2 is also a splicing
factor kinase that colocalizes with SRSF1 in nuclear speckles.
It interacts with and phosphorylates SRSF1, affecting the
splicing activity of SRSF1 in a SRPK1-independent manner
[40].
4. SRSF1 Regulation through
Nuclear-Cytoplasmic Distribution
Ample experimental evidence showed that SRSF1 is a shut-
tling protein that localizes to both the nucleus and the
cytoplasm, depending on the phosphorylation state of its
RS domain [37, 41]. Furthermore, experimental blocking of
SRPK (by either depleting its expression level or inhibiting its
kinase activity) revealed that the cytoplasmic pool of SRSF1
increased, identifying phosphorylation as a major factor for
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Figure 1: Life cycle and posttranslational modifications of the SRSF1 protein. Following its de novo synthesis at ribosomes, the cytoplasmic
SRSF1 protein is constitutively phosphorylated by the cytosolic protein kinase SRPK at serine residues in the proximal RS domain (pRS).This
first phosphorylation step is required for nuclear import of SRSF1, followed by a second phosphorylation step at the distal RS domain (dRS),
including several serine-proline (SP) motifs. This step is usually catalyzed by the nuclear protein kinase CLK1 but can also be performed by
SRPK if induced to translocate into the nucleus. Nuclear translocation is furthermodulated throughmethylation of the three arginine residues
R93, R97, and R109 located between the two RNA recognition motif (RRM) domains (not shown). SRSF1 with a completely phosphorylated
RS domain accumulates in nuclear speckles from where it is recruited to the spliceosome. SRSF1 dephosphorylation induces its nuclear to
cytoplasmic translocation and lack of phosphorylation by SRPK in the cytosol leads to its proteolytic degradation.
SRSF1 nuclear translocation [42, 43]. The contribution of
nuclear phosphatase activity to cytoplasmic export of SRSF1
has not been directly demonstrated in vivo but protein
phosphatase 1 can dephosphorylate the proximal RS domain
of SRSF1 in vitro or in permeabilized cell nuclei [44–46].
One physiological condition modulating SRSF1 localiza-
tion is stress response, when general splicing is inhibited but
specific alternative splicing events continue to occur [47]. For
example, replicative senescence or induced stress stimuli of
the vascular endothelium result in preferential cytoplasmic
localization of SRSF1 and the underlyingmechanismwas pos-
tulated to involve nuclear import of SRPK1 and consequently
lack of constitutive cytosolic SRSF1 phosphorylation [48]. In
contrast, hyperphosphorylation of SRSF1 was observed dur-
ing the DNA damage response and caused altered subnuclear
distribution and changes in alternative splicing pattern of
target genes [49].
Another posttranslationalmodification involved in SRSF1
localization is the methylation of three arginine residues
(R93, R97, and R109) located in a region between the two
RRM domains [50]. Lack of methylation in a triple-Ala
mutant turned SRSF1 predominantly cytoplasmic, whereas
a triple-Lys substitution maintaining the positive charge
localized to nuclear speckles, as the wild-type protein. How
the respective protein arginine methyltransferases (PRMTs)
are regulated and contribute to the nuclear-cytoplasmic
transitions of SRSF1 is poorly understood.
Once in the nucleus, the long noncoding RNA MALAT1
(metastasis-associated lung adenocarcinoma transcript 1)
interacts with SRSF1, which is important for the recruitment
of other SR proteins into nuclear speckles [51].
5. Functional Consequences of Nuclear versus
Cytoplasmic SRSF1 Concentrations
Relative concentrations of antagonizing or competing SFs are
important determinants in alternative splicing regulation. For
example, SRSF1 generally displays a stimulatory role in splic-
ing when bound to exons and its function in alternative splic-
ing in vitro can be antagonized by the activity of hnRNP A
proteins in a concentration-dependent manner. In vivo, com-
petition between SFs can originate from the relative ratios
of such antagonists expressed in different tissues or devel-
opmental stages, creating tissue or stage-specific patterns of
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splicing. In addition, the dynamic regulation of subcellular
SF localization allows cells to modulate the effective nuclear
concentration of a given SF and alter the pattern of expressed
splicing variants in response to external stimuli. For example,
the subnuclear distribution of SRSF1 changes during the
DNA damage response following hyperphosphorylation and
results in a shift in the alternative splicing pattern of target
genes that control cell survival [49]. Also, drug-induced
disruption of nuclear speckles with concomitant release of
SRSF1 into the nucleoplasm induced changes in alternative
splicing events [52]. And endothelial senescence is associated
with a scattered distribution of SRSF1 throughout the cyto-
plasm. This leads to the expression of alternative isoforms
of target genes such as endoglin (ENG), vascular endothelial
growth factor A (VEGFA), tissue factor (T3), or lamin A
(LMNA) that integrate into a commonmolecular senescence
program [48]. Vice versa, epithelial cells treated with insulin-
like growth factor-1 (IGF-1) displayed nuclear translocation
of SRSF1, which was dependent on SPRK1/2 activity.
6. Regulation of SRSF1 by
Cytosolic Protein Degradation
A specific decrease in SRSF1 protein levels was observed
in SRPK1-depleted or SRPIN340-treated colorectal cells,
without changes in the corresponding SRSF1 mRNA. This
suggests that cytoplasmic SRSF1 localization leads to protein
degradation. Indeed, the SRSF1 protein remained stable in
such treated cells when incubated with inhibitors MG132 or
lactacystin, indicating degradation by the proteasome [43]. It
should be noted that studying SFs with proteasome inhibitors
needs to be well controlled at the corresponding transcript
level because the inhibitors are likely to affect other SFs
or transcription factors in the cell. For example, the gene
encoding SRSF3 (former SRp20) is a direct transcriptional
target of 𝛽-catenin/TCF4 [53] so that inhibition of 𝛽-catenin
degradation will increase expression of SRSF3, which in turn
can promote unproductive alternative SRSF1 transcripts [54].
SRSF1 protein expression levels did also not correlate
with mRNA expression levels following T cell stimulation.
Immunoprecipitation studies showed increased ubiquityla-
tion of SRSF1 in activated T cells and proteasomal but not
lysosomal degradation was shown to be involved by blocking
with specific inhibitors MG132 and bafilomycin, respectively.
Interestingly, T cells from patients with SLE (systemic lupus
erythematosus) showed increased ubiquitylation of SRSF1
when compared to those from healthy individuals [55].
Downregulation of SRSF1 protein level was further found
to occur following inhibition of activity or siRNA-mediated
depletion of GSK3𝛽 in U87 or U373 glioblastoma cells [56].
Similarly, GSK3𝛽 depletion in HT29 colorectal cancer cells
led to a reduction in both SRSF1 and SRPK1 protein levels,
suggesting an indirect effect of GSK3𝛽 on SRSF1 via SRPK1
[43].
It has been described that the RS domain, which is
common to all SR proteins, is required for their proteolytic
degradation by the proteasome [57] but further mechanistic
details remain to be determined.
7. Impact of Posttranslational Modification on
Other RNA-Related Functions of SRSF1
SRSF1 has been shown to facilitate the nuclear export of
spliced mRNAs to which it is bound through its interaction
with the TAP/NXF1 receptor [58]. Interestingly, this adaptor
function implies partial dephosphorylation of its RS domain
for cytoplasmic translocation [59], suggesting the phospho-
rylation status of SRSF1 serves to regulate nuclear export of
some mRNPs.
The subsequent ribosomal translation of transcripts con-
taining a SRSF1-targeted ESE is also stimulated, both in
vivo and in vitro [60]. Thus, SRSF1-mediated alternative
splicing, mRNA export, and translational efficiency of its
target transcripts are coupled, and their number has been
identified experimentally to be around 500 [61].
In addition, SRSF1 overexpression was found to increase
the ratio between cap-dependent and internal ribosome
entry site-dependent translation initiation [62], probably by
suppressing the activity of 4E-BP, a competitive inhibitor
of cap-dependent translation [63]. Probably related to these
properties is the observation that SRSF1 enhances nonsense-
mediated mRNA decay (NMD) [64] because SRSF1 over-
expression can promote the pioneer round of translation
required for NMD to occur [58].
Another class of RNA pol2 transcripts is miRNAs and
SRSF1 overexpression in HeLa cells promoted the maturation
step ofmiR-7 and othermiRNAs. SRSF1 (and also other splic-
ing factors) directly interacts with primary miR transcripts
and promotes the Drosha cleavage step generating mature
miRNA [65].
Another recently discovered function of SRSF1 is to
enhance protein sumoylation [66]. SRSF1 associates with the
SUMO E2 conjugating enzyme Ubc9 and enhances SUMO
conjugation to RNA processing factors but further details on
the regulation or consequences of this modification remain
to be identified.
It should also be noted that SRSF1 was shown to be
involved in chromatin organization and histone modifica-
tions such as H3K36me3, which are relevant for splicing
decisions [67, 68].
8. Role of SRSF1 in Cancer Cell Biology
and Tumorigenesis
Malignant changes in the cellular genome can either be
tumor-initiating driver events or subsequent adaptations
required for tumor cell progression. Such changes either
alter the expression level of critical genes or their nucleotide
sequence to generate gain- or loss-of-function mutant gene
products. Although point mutations in core components
of the spliceosome were recently discovered using whole-
genome sequencing approaches [69], reports from various
tumor types revealed that splicing factors mostly show
increased expression levels [70–72]. Concerning SRSF1, over-
expression was reported in tumors from colon, thyroid,
small intestine, kidney, lung, liver, pancreas, and breast
[73, 74]. In childhood acute lymphoblastic leukemia SRSF1
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was further found to be upregulated together with protein
arginine methyltransferase PRMT1 [75], which is involved in
promoting SRSF1 nuclear localization [50].
The overexpression of SRSF1 in tumors has been related
to several alternativemechanisms. First, in breast tumors and
breast cancer cell lines amplification of the SFRS1 gene at
chromosomal location 17q23 was detected and the increased
DNA copy number correlated with elevated SRSF1 mRNA
levels [73].
Second, the SRSF1 gene is a target ofMYC, a potent onco-
genic transcription factor overexpressed in many different
tumor types that has pleiotropic effects on cancer cell biology
[76]. MYC binds directly to the SRSF1 promoter and activates
transcription. Both geneswere found coexpressed in lung and
breast carcinomas and MYC depletion downregulates SRSF1
expression in lung cancer cell lines [77].
Third, the above-mentioned negative feedback loop, in
which SRSF1 promotes an increase in unproductive splice
variants of its own transcripts, can be subverted in the
presence of splicing regulator SAM68. Changes in expression
or phosphorylation of SAM68 were found to promote the
formation of full-length SRSF1 transcripts, thus leading to
increased SRSF1 protein levels [10]. SAM68 phosphorylation
depends on ERK/MAP kinase activity, which is frequently
augmented in human tumors.
Together, this indicates that SRSF1 overexpression is in
general the consequence of other preceding tumor-initiating
genetic changes but contributes to further tumor progression.
Two apparently opposing consequences of SRSF1 over-
expression on cancer cell biology have been described: the
induction of oncogene-induced senescence and the malig-
nant transformation of cells. On the one hand, SRSF1 over-
expression leads to the formation of a nucleoplasmic com-
plex with the ribosomal protein RPL5 and the E3-ubiquitin
ligase MDM2, which normally ubiquitylates the p53 tumor-
suppressor protein leading to its proteolytic degradation [78].
Complex formation inhibits MDM2 and thus p53 protein
levels increase and trigger a cellular senescence response,
which normally is part of a ribosomal stress pathway. Because
the ability of SRSF1 overexpression to activate a tumor-
suppressing senescence response is dependent on an intact
p53 pathway, the identified SRSF1-overexpressing tumor
types revealed characteristics of p53 inactivation [78].
On the other hand, SRSF1 can act as an oncogene since
a twofold increase in expression can transform immortalized
rodent fibroblasts [73, 79] and human mammary epithelial
cells [73, 79]. In these models, SRSF1 overexpression pro-
moted cell proliferation and antiapoptotic pathways, mainly
reflecting the combined effects of several alternative splic-
ing variants which were activated by the concentration-
dependent changes in SRSF1 availability. Some of these
specific variants have been characterized, as detailed below,
but probably represent just the tip of the iceberg.
One group of identified target genes is formed by the
apoptosis regulators BIN1, BCL2L11 (BIM), BCL-XL, ICAD,
and MCL1, with SRSF1 overexpression in cancer cells pro-
moting the formation of their respective antiapoptotic splice
variants. Several target genes belong to the Bcl-2 family of
proteins, which regulate whether the Bak and Bax proteins
can cause mitochondrial outer membrane permeabilization
and cytochrome c release as the trigger for intrinsic apoptosis
induction. The Bcl-2 family comprises both proapoptotic
and antiapoptotic proteins, depending on their BH domain
composition, and it is the balance between both types of
proteins that determines whether the mitochondrial pathway
to apoptosis is activated [80].
Regarding BIM, several SRSF1-induced transcript vari-
ants were described lacking exons 2, 3, or 4 (BIM 𝛾1, 𝛾2,
ES) which encode the BH3 domain. This domain binds
antiapoptotic Bcl-2 family members and is necessary for
induction of apoptosis by BIM [79, 81]. Similarly, SRSF1
expression promotes inclusion of exon 2 of the BH3 domain-
containing gene MCL-1 (myeloid cell leukemia-1) giving rise
to the antiapoptotic MCL-1L isoform in both breast cancer
and choriocarcinoma cells [82]. Overexpression of SRSF1 also
promotes generation of the antiapoptotic isoform BCL-XL
[83].
BIN1 has tumor-suppressor activity by interacting with
and activating MYC-mediated apoptosis, except when exon
12A is included by SRSF1-mediated alternative splicing,
because the resulting antiapoptotic BIN1+12A isoform is
unable to interact withMYC. Furthermore, SRSF1 was shown
to modulate exclusion of exon 5 of the mRNA encoding
the inhibitor of caspase-activated DNase (ICAD), a regulator
of the DNase responsible for DNA fragmentation during
apoptosis [84].
A parallel group of SRSF1-regulated target genes is
involved in cellular signaling pathways related to proliferation
and cell cycle progression. Examples of genes from this group
are CCND1, RPS6KB1, RON, RAC1, andMKNK2 genes.
SRSF1 increases expression of the cyclin D1b oncogene
which arises from alternative splicing of the CCND1 tran-
script, and harbors enhanced oncogenic functions not shared
by full-length cyclin D1 (cyclin D1a) [85]. In this case, SRSF1
blocks recognition of the CCND1 exon 4-intron 4 boundary,
thus repressing inclusion of exon 5 so that a nuclear protein
with a unique C-terminus is generated. SRSF1 also promotes
the inclusion of exon 5 into the pre-mRNAs of TEAD-1 (TEF-
1 or TCF13), a transcription factor normally involved in cell
differentiation and cell cycle arrest in myoblasts [86].
The RPS6KB1 gene encodes the protein S6 kinase 1, a
substrate for the cell growth regulating kinase mTOR. Excess
SRSF1 promoted an increase in S6K1 variants by including
one to three alternative cassette exons between exons 6 and
7 that are normally skipped [73] and include a proper stop
codon. These short S6K1 isoforms have a truncated kinase
domain and lack the mTOR-regulated C-terminus but are
able to bind to and activate the mTORC1 complex. This
activation of themTORC1 complex occurs independent of the
classical PI3K/AKT pathway and leads to phosphorylation
of eIF4EBP1, releasing its inhibitory effect on cap-dependent
translation [87, 88]. In addition, there is evidence that SRSF1
itself participates in a complex with mTORC1 to enhance
translation efficiency of its target transcripts [63], for exam-
ple, survivin [89] and 𝛽-catenin [90].
RON encodes a receptor tyrosine kinase in breast and
colon tumors and SRSF1 promotes skipping of exon 11 by
binding to an enhancer element in the competing exon 12.
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The resulting isoform ΔRon is constitutively active and pro-
motes cell motility [91] as part of an epithelial-mesenchymal
transition program,which tumor cellsmay use to escape from
adverse local growth conditions.
Breast and colon tumors are further characterized by
overexpression of Rac1b [92, 93], a hyperactivated splice
variant of the small GTPase Rac1, which is involved in gene
transcription and cell motility [94, 95]. In colorectal cells,
SRSF1 was shown to be required for inclusion of an additional
exon 3b to generate Rac1b [96] and increased expression of
Rac1b contributes to cell survival [97, 98].
Finally, SRSF1 overexpression enhances the inclusion of
the alternative 3󸀠-terminal exon 13b of the gene MKNK2
encoding the protein kinase Mnk2, an effector in the
ERK/MAPK pathway [73]. The corresponding isoform
Mnk2b lacks a C-terminal MAPK-binding domain and does
not phosphorylate and activate the p38-MAPK required for
stress-induced cell death. In contrast, it sustains phosphoryla-
tion of the translation initiation factor eIF4E, thus promoting
cap-dependent protein translation and cell growth [99].
Curiously, splicing of theMnk2b isoformwas not induced
when a chimeric nucleus-retained SRSF1 protein (SRSF1-
NRS1), fused to the nuclear retention signal of the non-
shuttling protein SRSF2, was overexpressed, suggesting an
indirect effect of SRSF1 for this splicing event. Nevertheless,
SRSF1-NRS1was as competent aswild-type SRSF1 in inducing
mammary cell transformation in 3D cultures but requires
presence of the RRM1 domain, revealing a significant contri-
bution of the nuclear functions of SRSF1 to cell transforma-
tion [79].
In hepatocellular xenografts, however, SRSF1-NRS1 pro-
tein had a much lower effect on tumor formation than SRSF1.
In this model, SRSF1 overexpression also promotes activa-
tion of ERK/MAPK, probably by increasing B-RAF mRNA
and protein levels. Although the mechanism remains to be
explained, the RRM1 domain is required and sufficient to
induce activation of this oncogenic pathway, indicating that
the effect occurs at themRNA level [81].These findings reveal
that SRSF1 can exert its oncogenic role through both nuclear
and cytosolic pathways depending on the cellular contexts.
More recently, SRSF1 overexpression was also reported in
lung cancer and novel SRSF1 target transcripts were identi-
fied, including the genes, ATP11C, IQCB1, TUBD1, proline-
rich coiled-coil 2C (PRRC2C) [100], and survivin [89].
Apart from the genetic changes affecting proliferation
and survival of the transformed cancer cells themselves,
another important aspect of cancer cell biology is their
cellular communication with the surrounding stroma. It is
imperative for the growth of epithelial tumors to gain access
to nutrient supply via blood vessels so that cancer cells release
angiogenic signals to endothelial cells, for instance, the
vascular endothelial growth factor VEGF. SRSF1 is involved
in promoting proximal splice site selection in C-terminal
exon 8 of VEGF, resulting in the generation of proangiogenic
isoforms [101, 102]. Besides overexpression, this can result
from SRSF1 activation in epithelial cells following oncogenic
signaling through IGF-1, EGF, or TNF-𝛼. These factors lead
to activation of SRPKs [26, 42], which then phosphorylate SR
proteins including SRSF1. SRPK1 inhibition has been used to
manipulate the local balance of pro- and antiangiogenic in eye
pathologies caused by neovascularization [103] and might be
interesting for cancer therapy. In addition, SRSF1-mediated
alternative splicing of both Ron and TEAD-1 has been linked
to increased expression of angiogenic growth factors [77,
104]. SRSF1 may thus impact VEGF expression through both
direct and indirect regulation to promote angiogenesis.
The role of fibroblasts in the stroma is to deposit
or remodel extracellular matrix components and this is
important for tumor cell migration. For example, a dense
fibronectin meshwork favors epithelial cell invasion and
results from inclusion of the EDA exon through SRSF1-
regulated alternative splicing of the unique fibronectin-
encoding gene [105, 106]. This occurs during embryogenesis
but also in adult fibroblasts during tissue repair, tumor pro-
gression, and inflammation when expression levels of SRSF1
increase. It remains to be established whether tumor cells
can release signals that induce increased SRSF1 expression in
tumor-associated fibroblasts.
Following therapeutic challenge of tumor cells withDNA-
damaging agents, resistant cells can eventually emerge. In
one report hyperphosphorylation of SRSF1 was observed in
the presence of DNA damage, causing altered subnuclear
distribution and changes in alternative splicing pattern of
target genes that promote cell survival [49]. Similarly, treat-
ment of pancreatic tumor cells with the nucleoside analogue
gemcitabine induced SRSF1 overexpression, and the resulting
splicing of MNK2b with consequent phosphorylation of
the translation initiation factor eIF4E was identified as the
cause for drug resistance [107]. Furthermore, non-small
cell lung cancer (NSCLC) cells respond to daunorubicin
or cisplatin with an antiapoptotic caspase 9b splice variant.
SRSF1 regulates this alternative splicing event by binding to
a splicing enhancer in intron 6 and subsequent exclusion of
an exon 3,4,5,6-cassette, generating caspase 9b [108]. SRSF1
is activated following hyperphosphorylation at serines 199,
201, 227, and 234 [109], mediating the therapeutic resistance
of NSCLC. Another study in NSCLC observed that SRSF1
protein accumulates when cells were treated with carboplatin
and paclitaxel and that cells stably overexpressing SRSF1 were
more resistant to these chemotherapeutic drugs [74].
9. Conclusions
SRSF1 is an important protein for the regulation of con-
stitutive and alternative splicing of cellular pre-mRNAs.
Its activity as splicing regulator depends on the relative
expression level of SRSF1 compared to other antagonistic or
synergistic splicing factors as well as on its posttranslational
modifications. In particular, the phosphorylation state of
SRSF1 determines its nuclear or cytoplasmic localization and
proteolytic degradation. Overexpression of SRSF1 has been
reported in various tumors types and this has consequences
for the alternative splicing profile expressed in tumor cells.
Clear experimental evidence for tumor-promoting effects of
SRSF1-induced alternative splicing variants has been pro-
vided but the genome-wide scale of its effects on cancer cell
biology remains to be described.
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Similar studies on other splicing factors are beginning to
emerge and will likely reveal comparable complex effects on
cancer cell transcriptomes as part of an adaptive response to
activate survival pathways in tumor cells. Amore comprehen-
sive knowledge of these pathways may allow designing ther-
apeutic interventions based on a combination of inhibitory
drugs targeting simultaneously various pathways to reduce
the selection of therapy-resistant tumor cell clones.
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